John V - G1 Therapeutics Chief Officer
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
Executive
John V is Chief Officer of G1 Therapeutics
| Age | 39 |
| Phone | 919 213 9835 |
| Web | https://www.g1therapeutics.com |
G1 Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.192) % which means that it has lost $0.192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0901) %, meaning that it created substantial loss on money invested by shareholders. G1 Therapeutics' management efficiency ratios could be used to measure how well G1 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.G1 Therapeutics currently holds 57.17 M in liabilities with Debt to Equity (D/E) ratio of 1.24, which is about average as compared to similar companies. G1 Therapeutics has a current ratio of 4.66, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about G1 Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Stephen Young | Arcus Biosciences | 55 | |
| Ryan Fischesser | Caribou Biosciences | N/A | |
| Snehal Patel | Sana Biotechnology | N/A | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Jamie MD | Annexon | 66 | |
| Barbra Sasu | Allogene Therapeutics | N/A | |
| Richard Mulligan | Sana Biotechnology | 69 | |
| Lars MBA | PDS Biotechnology Corp | 54 | |
| Christina Rossi | Blueprint Medicines Corp | 47 | |
| JD Esq | Acumen Pharmaceuticals | 53 | |
| JD Esq | Caribou Biosciences | 69 | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| John Berman | Larimar Therapeutics | N/A | |
| Shikhar MBA | Annexon | N/A | |
| Brett Fleshman | Heron Therapeuti | N/A | |
| Paul Reider | Coherus BioSciences | 54 | |
| Julian Baker | Blueprint Medicines Corp | 57 | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Jennifer Jarrett | Arcus Biosciences | 50 | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 |
G1 Therapeutics Leadership Team
Elected by the shareholders, the G1 Therapeutics' board of directors comprises two types of representatives: G1 Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GTHX. The board's role is to monitor G1 Therapeutics' management team and ensure that shareholders' interests are well served. G1 Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, G1 Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Monica Thomas, General Officer | ||
| Jay Strum, Chief Scientific Officer | ||
| Andrew Perry, Chief Officer | ||
| Jeff Macdonald, Head of Investor Relations/Public Relations | ||
| Jennifer CPA, Chief Officer | ||
| Alexander MS, VP Operations | ||
| John V, Chief Officer | ||
| ChB MB, Chief RD | ||
| Terry MSc, Chief Officer | ||
| John Bailey, President CEO | ||
| William Roberts, Vice Communications | ||
| Mark Avagliano, Chief Officer | ||
| Evan MBA, Vice Marketing | ||
| Terry Murdock, Senior Vice President - Development Operations |
GTHX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is G1 Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.77) % | |||
| Operating Margin | (0.21) % | |||
| Current Valuation | 364.46 M | |||
| Shares Outstanding | 52.76 M | |||
| Shares Owned By Insiders | 10.92 % | |||
| Shares Owned By Institutions | 54.61 % | |||
| Number Of Shares Shorted | 3.41 M | |||
| Price To Earning | (1.95) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |